Mankind Pharma agrees €48 million investment in Armed Cell Therapeutics
The proposed 70% stake would give Mankind an interest in a biotechnology business developing next-generation CAR-T candidates.

Edivro Company News · Original attributed summary. Source announcement: 2026-10-15.
Mankind Pharma has entered a definitive agreement to invest €48 million for a 70% stake in Armed Cell Therapeutics. The transaction is being undertaken through Mankind Pharma (Netherlands) B.V., according to the company’s 15 October announcement.
What does Armed Cell Therapeutics develop?
The biotechnology business is developing next-generation CAR-T candidates, with lead programmes focused on non-Hodgkin lymphoma and small cell lung cancer. Mankind describes research and development teams in the US and Europe, alongside work on in-vivo CAR-T cell generation.
The announcement names Paul Stoffels as chair of Armed Cell Therapeutics and John Mellors as chief scientific officer. It places the investment within Mankind’s stated strategy of building an innovation-led pharmaceutical business.
What does the agreement establish?
The release establishes an agreed investment and intended majority stake. It does not present the transaction as proof that a therapy is approved, available to patients or clinically effective. Development candidates, clinical evidence and regulatory authorisation are separate matters.
Mankind says the investment is intended to build access to scientific platforms and a pipeline of potential therapies. The commercial outcome depends on subsequent development and other conditions described in the company’s forward-looking statements. No treatment recommendation follows from this acquisition announcement.
Questions about this story
These answers summarise the article and refer to its original reporting period.
What does Armed Cell Therapeutics develop?
The biotechnology business is developing next-generation CAR-T candidates, with lead programmes focused on non-Hodgkin lymphoma and small cell lung cancer. Mankind describes research and development teams in the US and Europe, alongside work on in-vivo CAR-T cell generation.
What does the agreement establish?
The release establishes an agreed investment and intended majority stake. It does not present the transaction as proof that a therapy is approved, available to patients or clinically effective. Development candidates, clinical evidence and regulatory authorisation are separate matters.
Publisher
Edivro Company News

